Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C4 Therapeutics RET compound 20
- Development stage
- Unknown
- Lead developer
- C4 Therapeutics, Inc.
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules
01
Overview
C4 Therapeutics RET compound 20: sourced facts only. name: "Here we describe the medicinal chemistry efforts that led to compound 20, an orally bioavailable, brain-penetrant, pan-mutant and pan-fusion RET heterobifunctional degrader." [PMID:40823490]; target: "Here we describe the medicinal chemistry efforts that led to compound 20, an orally bioavailable, brain-penetrant, pan-mutant and pan-fusion RET heterobifunctional degrader." [PMID:40823490]; developer: "C4 Therapeutics 490 Arsenal Way, Suite 120 Watertown MA 02472 USA [email protected]." [PMID:40823490]; modality: "Here we describe the medicinal chemistry efforts that led to compound 20, an orally bioavailable, brain-penetrant, pan-mutant and pan-fusion RET heterobifunctional degrader." [PMID:40823490]
02
Targets
RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on C4 Therapeutics RET compound 20.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C4 Therapeutics RET compound 20.